Ocular Hypertension – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Ocular Hypertension - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ocular Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ocular Hypertension. Ocular Hypertension - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Summary
Global Markets Direct’s, 'Ocular Hypertension - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ocular Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ocular Hypertension. Ocular Hypertension - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Ocular Hypertension.
- A review of the Ocular Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ocular Hypertension pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
- Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Ocular Hypertension Overview
Therapeutics Development
An Overview of Pipeline Products for Ocular Hypertension
Ocular Hypertension Therapeutics under Development by Companies
Ocular Hypertension Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Ocular Hypertension Therapeutics – Products under Development by Companies
Ocular Hypertension Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Ocular Hypertension Therapeutics Development
Alcon, Inc.
F. Hoffmann-La Roche Ltd.
Bausch & Lomb Incorporated
Allergan, Inc.
QLT Inc.
Santen Incorporated
Santen Pharmaceutical Co., Ltd.
Sylentis
Novagali Pharma SA
Kowa Company, Ltd.
Ono Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Limited
LABORATOIRES THEA
Senju Pharmaceutical Co., Ltd.
Asahi Kasei Pharma
Inotek Pharmaceuticals Corporation
Aerie Pharmaceuticals, Inc.
Ocular Hypertension – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
tafluprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tafluprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BOL-303259-X - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INO-8875 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
K-115 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-12286 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SYL-040012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HPP-851 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Brinzolamide + Brimonidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RKI-983 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RO-5093151 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-99 Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-12286 + Latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
acetazolamide sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AGN-207281 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-2345 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aganepag isopropyl - Drug Profile
Product Description
Mechanism of Action
R&D Progress
simenepag - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPA-6566 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
timolol maleate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DE-112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dorzolamide Hydrochloride + Brimonidine Tartrate + Timolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL-59412C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL-54478 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DE-111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brimonidine tartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-13324 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-12286 + Travoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONO-9054 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATS-907 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATS-8535 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DE-117 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ocular Hypertension Therapeutics – Drug Profile Updates
Ocular Hypertension Therapeutics – Discontinued Products
Ocular Hypertension Therapeutics - Dormant Products
Ocular Hypertension – Product Development Milestones
Featured News & Press Releases
Jun 13, 2012: Zeltia Subsidiary Sylentis Commences Phase II Clinical Trial With SYL040012 For Treatment Of Ocular Hypertension Associated With Glaucoma
Apr 20, 2012: Senju Pharma To Launch AIPHAGAN Ophthalmic Solution In Japan
Apr 09, 2012: RegeneRx Receives Four New Patents And Allowances In Mexico And Israel
Mar 13, 2012: NicOx, Bausch + Lomb's Glaucoma Candidate BOL-303259-X Meets Primary Endpoint In Phase IIb Study
Feb 13, 2012: FDA Approves Merck's ZIOPTAN For Treatment Of Intraocular Pressure In Glaucoma Patients
Feb 09, 2012: Altheos Initiates Phase IIa Clinical Trial For Its Lead Glaucoma Drug Candidate, ATS907
Nov 28, 2011: NicOx Announces Completion Of Patient Recruitment In Glaucoma Study
Sep 13, 2011: Acucela And Otsuka Pharmaceutical Announce Initiation Of Phase I/II Clinical Trial For OPA-6566 In Patients With Open-Angle Glaucoma Or Ocular Hypertension
Sep 08, 2011: Novagali Pharma Reports Positive Results In Phase II Study For Catioprost Versus Travatan Z In Patients With Glaucoma And Ocular Surface Disease
Jul 21, 2011: Inotek To Expand Phase II Clinical Trial In Glaucoma Based On Promising Preliminary Results
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Ocular Hypertension, H2 2012
Products under Development for Ocular Hypertension – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Development by Companies, H2 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Alcon, Inc., H2 2012
F. Hoffmann-La Roche Ltd., H2 2012
Bausch & Lomb Incorporated, H2 2012
Allergan, Inc., H2 2012
QLT Inc., H2 2012
Santen Incorporated, H2 2012
Santen Pharmaceutical Co., Ltd., H2 2012
Sylentis, H2 2012
Novagali Pharma SA, H2 2012
Kowa Company, Ltd., H2 2012
Ono Pharmaceutical Co., Ltd., H2 2012
Sun Pharmaceutical Industries Limited, H2 2012
LABORATOIRES THEA, H2 2012
Senju Pharmaceutical Co., Ltd., H2 2012
Asahi Kasei Pharma, H2 2012
Inotek Pharmaceuticals Corporation, H2 2012
Aerie Pharmaceuticals, Inc., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Ocular Hypertension Therapeutics – Drug Profile Updates
Ocular Hypertension Therapeutics – Discontinued Products
Ocular Hypertension Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Ocular Hypertension, H2 2012
Products under Development for Ocular Hypertension – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Discovery and Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Global Markets Direct Report Coverage
Ocular Hypertension Overview
Therapeutics Development
An Overview of Pipeline Products for Ocular Hypertension
Ocular Hypertension Therapeutics under Development by Companies
Ocular Hypertension Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Ocular Hypertension Therapeutics – Products under Development by Companies
Ocular Hypertension Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Ocular Hypertension Therapeutics Development
Alcon, Inc.
F. Hoffmann-La Roche Ltd.
Bausch & Lomb Incorporated
Allergan, Inc.
QLT Inc.
Santen Incorporated
Santen Pharmaceutical Co., Ltd.
Sylentis
Novagali Pharma SA
Kowa Company, Ltd.
Ono Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Limited
LABORATOIRES THEA
Senju Pharmaceutical Co., Ltd.
Asahi Kasei Pharma
Inotek Pharmaceuticals Corporation
Aerie Pharmaceuticals, Inc.
Ocular Hypertension – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
tafluprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tafluprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BOL-303259-X - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INO-8875 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
K-115 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-12286 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SYL-040012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HPP-851 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Brinzolamide + Brimonidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RKI-983 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RO-5093151 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-99 Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-12286 + Latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
acetazolamide sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AGN-207281 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-2345 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aganepag isopropyl - Drug Profile
Product Description
Mechanism of Action
R&D Progress
simenepag - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPA-6566 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
timolol maleate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DE-112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dorzolamide Hydrochloride + Brimonidine Tartrate + Timolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL-59412C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL-54478 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DE-111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brimonidine tartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-13324 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-12286 + Travoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONO-9054 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATS-907 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATS-8535 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DE-117 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ocular Hypertension Therapeutics – Drug Profile Updates
Ocular Hypertension Therapeutics – Discontinued Products
Ocular Hypertension Therapeutics - Dormant Products
Ocular Hypertension – Product Development Milestones
Featured News & Press Releases
Jun 13, 2012: Zeltia Subsidiary Sylentis Commences Phase II Clinical Trial With SYL040012 For Treatment Of Ocular Hypertension Associated With Glaucoma
Apr 20, 2012: Senju Pharma To Launch AIPHAGAN Ophthalmic Solution In Japan
Apr 09, 2012: RegeneRx Receives Four New Patents And Allowances In Mexico And Israel
Mar 13, 2012: NicOx, Bausch + Lomb's Glaucoma Candidate BOL-303259-X Meets Primary Endpoint In Phase IIb Study
Feb 13, 2012: FDA Approves Merck's ZIOPTAN For Treatment Of Intraocular Pressure In Glaucoma Patients
Feb 09, 2012: Altheos Initiates Phase IIa Clinical Trial For Its Lead Glaucoma Drug Candidate, ATS907
Nov 28, 2011: NicOx Announces Completion Of Patient Recruitment In Glaucoma Study
Sep 13, 2011: Acucela And Otsuka Pharmaceutical Announce Initiation Of Phase I/II Clinical Trial For OPA-6566 In Patients With Open-Angle Glaucoma Or Ocular Hypertension
Sep 08, 2011: Novagali Pharma Reports Positive Results In Phase II Study For Catioprost Versus Travatan Z In Patients With Glaucoma And Ocular Surface Disease
Jul 21, 2011: Inotek To Expand Phase II Clinical Trial In Glaucoma Based On Promising Preliminary Results
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Ocular Hypertension, H2 2012
Products under Development for Ocular Hypertension – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Development by Companies, H2 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Alcon, Inc., H2 2012
F. Hoffmann-La Roche Ltd., H2 2012
Bausch & Lomb Incorporated, H2 2012
Allergan, Inc., H2 2012
QLT Inc., H2 2012
Santen Incorporated, H2 2012
Santen Pharmaceutical Co., Ltd., H2 2012
Sylentis, H2 2012
Novagali Pharma SA, H2 2012
Kowa Company, Ltd., H2 2012
Ono Pharmaceutical Co., Ltd., H2 2012
Sun Pharmaceutical Industries Limited, H2 2012
LABORATOIRES THEA, H2 2012
Senju Pharmaceutical Co., Ltd., H2 2012
Asahi Kasei Pharma, H2 2012
Inotek Pharmaceuticals Corporation, H2 2012
Aerie Pharmaceuticals, Inc., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Ocular Hypertension Therapeutics – Drug Profile Updates
Ocular Hypertension Therapeutics – Discontinued Products
Ocular Hypertension Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Ocular Hypertension, H2 2012
Products under Development for Ocular Hypertension – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Discovery and Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
